

National Imaging Associates, Inc.*	
Clinical guidelines ENDOMETRIAL CANCER	Original Date: June 2013
Radiation Oncology	Last Revised Date: January 2022
Guideline Number: NIA_CG_129	Implementation Date: January 2023

INDICATIONS FOR RADIATION THERAPY AND TREATMENT OPTIONS

Post-operative¹

- Brachytherapy Only (HDR or LDR, 5 fx maximum)
 - Stage IA – with adverse risk factors
 - Stage IA – without risk factors (Grades G2, 3)
 - Stage IB
 - Stage II – (Grade G1)
- External Beam Radiation Therapy Only (2D, 3D-CRT, 45-50.4 Gy, 28 fx maximum)
 - Stage IA – with adverse risk factors (Grades G2, 3)
 - Stage IB – without adverse risk factors (Grade G3)
 - Stage IB – with risk factors
 - Stage II – (Grade G1)
 - Stage III
 - Stage IV
- External Beam (2D, 3D-CRT, 45-50.4Gy, 28 fx maximum) and Brachytherapy (HDR or LDR, 5 fx maximum)
 - Stage IA – with adverse risk factors (Grades G2, 3)
 - Stage IB – without risk factors (Grade G3)
 - Stage IB – with risk factors
 - Stage II – (Grades G1, 2, 3)
 - Stage IIIA & IIIB & IIIC (Grades G1, 2, 3)

Medically Inoperable/ Pre-Operative

- Brachytherapy Only (HDR or LDR, 7 fx maximum)
 - Stage I & II

* National Imaging Associates, Inc. (NIA) is a subsidiary of Magellan Healthcare, Inc.

- External Beam Radiation Therapy Only (2D, 3D-CRT, 45-50 Gy, 28 fx maximum)
 - All Stages
- External Beam (2D, 3D-CRT, 45-50.4 Gy) and Brachytherapy (HDR or LDR, 4 fx maximum)
 - All Stages

Palliative

- Up to 10 fx

Unless otherwise indicated, standard radiation fractionation consists of 1.8 Gy to 2.0 Gy per day.

TREATMENT OPTIONS REQUIRING ADDITIONAL CLINICAL REVIEW

Intensity Modulated Radiation Therapy (IMRT)

IMRT is not indicated as a standard treatment option and should not be used routinely for the delivery of radiation therapy for endometrial cancer.¹ IMRT is strictly defined by the utilization of inverse planning modulation techniques. IMRT may be appropriate for limited circumstances in which radiation therapy is indicated and 3D conformal radiation therapy (3D-CRT) techniques cannot adequately deliver the radiation prescription without exceeding normal tissue radiation tolerance, the delivery is anticipated to contribute to potential late toxicity or tumor volume dose heterogeneity is such that unacceptable hot or cold spots are created.

Clinical rationale and documentation for performing IMRT rather than 2D or 3D-CRT treatment planning and delivery will need to:

- Demonstrate how 3D-CRT isodose planning cannot produce a satisfactory treatment plan (as stated above) via the use of a patient-specific dose volume histograms and isodose plans.
- Provide tissue constraints for both the target and affected critical structures.

Post-Operative IMRT

IMRT for post-operative radiation therapy is approvable. If there is gross residual disease and the area(s) can be sufficiently utilized, a boost can be added to a total dose of 60-70Gy, respecting normal tissue sensitivity. For gross nodal disease, consider boost to 60-65Gy while respecting normal tissue constraints.¹

Stereotactic Body Radiation Therapy (SBRT)

Stereotactic Body Radiation Therapy is not a standard treatment option for the treatment of endometrial cancer.

Proton Beam Radiation Therapy

Proton beam is not an approved treatment option for endometrial cancer. Proton beam has not been proven superior treatment to conventional radiation therapy.¹

THE FOLLOWING APPLIES TO CMS (MEDICARE) MEMBERS ONLY

For Proton Beam and Stereotactic Radiotherapy, refer to Local Coverage Determination (LCD), if applicable.

BACKGROUND

Most endometrial cancers are adenocarcinomas, with uterine sarcomas accounting for <10%. This clinical guideline will focus primarily on adenocarcinoma of the endometrium.

After a diagnosis of endometrial cancer is made, it is followed by a staging evaluation to determine extent of disease (local, regional, or metastatic) and prognostic findings. For patients in whom cancers of the uterus are suspected, an endometrial biopsy is typically performed.¹ A review of the pathology will determine whether the tumors are of epithelial origin (endometrioid, papillary serous, clear cell, or carcinosarcoma) or stromal/mesenchymal carcinoma (stromal sarcoma or leiomyosarcoma). Most endometrial cancers, however, are adenocarcinomas with tumor typically confined to the uterus. Thus, this disease is often localized with an excellent prognosis. Current workup, including a complete surgical assessment, includes a histological grade, depth of myometrial invasion, and extent of extrauterine involvement. Prognostic factors are based on a pathologic assessment and include the percent of myometrial invasion, myometrial thickness, tumor size and location (upper fundus or lower uterine cervical), cervix involvement, and lymphovascular space involvement. Most patients are treated surgically with radiation reserved for patients who are deemed at a high risk of recurrence or for those deemed medically inoperable.²

This guideline outlines several methods suitable for the employment of radiation therapy. This includes the use of 3-dimensional conformal radiation therapy and/or internal radiation (brachytherapy). IMRT is not indicated as a standard treatment option for uterine cancer. External beam treatments are typically delivered using a high-energy linear accelerator. Brachytherapy is generally delivered using temporary HDR sources such as iridium-192. The purpose of this guideline is to outline the most efficient, comparatively effective, diagnostic and treatment pathway. Treatment is typically broken down into patients in whom disease is limited to the uterus, cervical involvement (either suspected or confirmed), or extrauterine disease.³

POLICY HISTORY

Date	Summary
January 2022	<ul style="list-style-type: none">Under Post-operative, changed external beam to 50.4 Gy for combination external beam and brachytherapyAdded Post-Operative IMRT under Treatment Options Requiring Additional Clinical Review
February 2021	No changes
February 2020	Updated references
February 2019	Added and updated references

REFERENCES

1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Uterine Neoplasms Version 1.2022. National Comprehensive Cancer Network (NCCN). Updated November 4, 2021. Accessed December 13, 2021. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf
2. Klopp A, Smith BD, Alektiar K, et al. The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline. *Pract Radiat Oncol*. May-Jun 2014;4(3):137-144. doi:10.1016/j.prro.2014.01.003
3. Elshaikh MA, Yashar CM, Wolfson AH, et al. ACR appropriateness Criteria® advanced stage endometrial cancer. *Am J Clin Oncol*. Aug 2014;37(4):391-6. doi:10.1097/coc.000000000000098

ADDITIONAL RESOURCES

1. Alektiar KM, Venkatraman E, Chi DS, Barakat RR. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. *Int J Radiat Oncol Biol Phys*. May 1 2005;62(1):111-7. doi:10.1016/j.ijrobp.2004.09.054
2. American College of Radiology. ACR Appropriateness Criteria®: Advanced Stage Endometrial Cancer. Updated 2014. Accessed October 12, 2021. <https://acsearch.acr.org/docs/3083084/Narrative/>
3. Blake P, Swart AM, Orton J, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. *Lancet*. Jan 10 2009;373(9658):137-46. doi:10.1016/s0140-6736(08)61767-5
4. American Society for Therapeutic Radiology and Oncology. Cervical and endometrial cancer patients report fewer side effects and better quality of life with IMRT. Updated 2016. Accessed October 12, 2021. https://www.astro.org/uploadedFiles/MAIN_SITE/News_and_Publications/News/News_Releases/2016/ASTRO_2016_Klopp.pdf
5. Bentzen SM, Constine LS, Deasy JO, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. *Int J Radiat Oncol Biol Phys*. Mar 1 2010;76(3 Suppl):S3-9. doi:10.1016/j.ijrobp.2009.09.040
6. Creutzberg CL, van Putten WL, Wárlám-Rodenhuis CC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. *J Clin Oncol*. Apr 1 2004;22(7):1234-41. doi:10.1200/jco.2004.08.159
7. Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. *Gynecol Oncol*. Mar 2009;112(3):543-52. doi:10.1016/j.ygyno.2008.11.014
8. Jackson A, Marks LB, Bentzen SM, et al. The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. *Int J Radiat Oncol Biol Phys*. Mar 1 2010;76(3 Suppl):S155-60. doi:10.1016/j.ijrobp.2009.08.074
9. Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. *Bjog*. Nov 2007;114(11):1313-20. doi:10.1111/j.1471-0528.2007.01332.x

10. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol*. Mar 2004;92(3):744-51. doi:10.1016/j.ygyno.2003.11.048
11. Kim DH, Lee JH, Ki YK, et al. Short-course palliative radiotherapy for uterine cervical cancer. *Radiat Oncol J*. Dec 2013;31(4):216-21. doi:10.3857/roj.2013.31.4.216
12. Kong A, Powell M, Blake P. The role of postoperative radiotherapy in carcinoma of the endometrium. *Clin Oncol (R Coll Radiol)*. Aug 2008;20(6):457-62. doi:10.1016/j.clon.2008.03.011
13. Kong A, Johnson N, Cornes P, et al. Adjuvant radiotherapy for stage I endometrial cancer. *Cochrane Database Syst Rev*. Apr 18 2007;(2):Cd003916. doi:10.1002/14651858.CD003916.pub2
14. Lee CM, Szabo A, Shrieve DC, Macdonald OK, Gaffney DK. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. *Jama*. Jan 25 2006;295(4):389-97. doi:10.1001/jama.295.4.389
15. Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. *Lancet*. Mar 6 2010;375(9717):816-23. doi:10.1016/s0140-6736(09)62163-2
16. Portelance L MJ, Jhingran A. A phase II multi-institutional study of postoperative pelvic Intensity Modulated Radiation Therapy (IMRT) with weekly Cisplatin in patients with cervical carcinoma: Two year efficacy results of the RTOG 0418. *International Journal of Radiation Oncology*. 2011;
17. Scholten AN, van Putten WL, Beerman H, et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. *Int J Radiat Oncol Biol Phys*. Nov 1 2005;63(3):834-8. doi:10.1016/j.ijrobp.2005.03.007
18. Shih KK, Milgrom SA, Abu-Rustum NR, et al. Postoperative pelvic intensity-modulated radiotherapy in high risk endometrial cancer. *Gynecol Oncol*. Mar 2013;128(3):535-9. doi:10.1016/j.ygyno.2012.11.020
19. Solhjem MC, Petersen IA, Haddock MG. Vaginal brachytherapy alone is sufficient adjuvant treatment of surgical stage I endometrial cancer. *Int J Radiat Oncol Biol Phys*. Aug 1 2005;62(5):1379-84. doi:10.1016/j.ijrobp.2005.01.026
20. Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. *Gynecol Oncol*. Jan 2008;108(1):226-33. doi:10.1016/j.ygyno.2007.09.029

Reviewed / Approved by NIA Clinical Guideline Committee

GENERAL INFORMATION

It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.

Disclaimer: Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates (“Magellan”). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.